ABSTRACT
Objective To investigate the characteristics of hepatitis virus B ( HBV) reactivation af-ter combined percutaneous microwave ablation ( PMWA ) and transcatheter arterial chemoembolization ( TACE) in patients with hepatocellular carcinoma ( HCC) and to study the therapeutic role of preoperative antiviral therapy .Methods The data on 180 HCC patients who were treated with the combined therapy were analyzed .The antivirus group ( n=90 ) received antiviral therapy , while the control group ( n=90 ) did not.HBV-DNA was used to study the reactivation status of HBV after the combined therapy and the role of antiviral therapy .Results The incidence of HBV reactivation was significantly lower in the antivirus group (8.2%, 7/90) than the control group (20.0%, 18/90, P<0.05).A preoperative HBV-DNA level above 104 copies/ml was the only independent risk factor of HBV reactivation (P<0.05).Conclusions The HBV reactivation rate was relatively high in patients with HBV-related HCC after combined PMWA and TACE.Preoperative antiviral therapy significantly reduced HBV reactivation and thus it should be adminis -trated especially to HCC patients with a preoperative HBV-DNA level above 104 copies/ml.
ABSTRACT
Hepatitis B recurrence is an important factor to show whether liver transplantation is successful or not. Recrrrence rate is nearly 80% in the patients liver transplantation, and HBV reinfection is the main cause of death. After the operation, HBV may copy very quickly, because of taking in immunosuppressant therapy and graft diseases develop rapidly. Recently, the exploitation and application of therapy has become a focus. Now the drugs of preventing and treating HBV reinfection are mainly sorted into passive immunity agents(Hepatitis B immunoglobulin) and antivirus therapeutic agents(interferon and nucleotide analog antivirus drugs, etc.). Lamivudine is considered the most promising new drug of treating HBV infection. This article introduced the therapeutic characteristic of these drugs.